Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 917-921

  Chow, Dominic C ^a   Tasaki, Anne ^a   Ono, Jill ^a   Shiramizu, Bruce ^a   Souza, Scott A ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Extended release niacin; HIV; Hormone sensitive lipase (HSL); Lipodystrophy syndrome; Lipoprotein lipase (LPL)

Indexed keywords

EID: 77954804098     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s3959     Document Type: Article

References (15)

1. Behrens GMN, Meyer-Olsen D, Stoll M, et al. 2003. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS, 17:S149-54.
2. Bodasing N, Fox R. 2003. HIV-associated lipodystrophy syndrome: description and pathogenesis. J Infect, 46:149-54.
3. Carr A. 2003. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS, 17:S141-8.
4. Farmer JA, Gotto AM. 1996. Choosing the right lipid-regulating agent: a guide to selection. Drugs, 52:649-61.
5. Fernandes APM, Sanches RS, Mill J, et al. 2007. Lipodystrophy syndrome associated with antiretroviral therapy in HIV patients: considerations for psychosocial aspects. Rev Latino-am Enfermagem, 15:1041-5.
6. Fessel WJ, Follansbee SE, Rego J. 2002. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS, 16:1785-9.
7. Gerber MT, Mondy KE, Yarasheski KE, et al. 2004. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis, 39:419-25.
8. Guyton JR, Blazing MA, Hagar J, et al. 2000. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med, 160:1177-84.
9. Leow MKS, Addy CL, Mantzoros CS. 2003. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab, 88:1961-76.
10. Montague CT, Prins JB, Sanders L, et al. 1998. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes, 47:1384-91.
11. Oh J, Hegele RA. 2007. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis, 7:787-96.
12. Reynisdottir S, Dauzats M, Thorne A, et al. 1997. Comparison of hormonesensitive lipase activity in visceral and subcutaneous human adipose tissue. J Clin Endocrinol Metab, 82:4162-6.
13. Schambelan M, Benson CA, Carr A, et al. 2002. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS society-USA panel. JAIDS, 31:257-75.
14. Souza SA, Chow DC, Walsh E, et al. 2002. A 36-week safety and tolerability study of extended-release niacin (ERN) for the treatment of hypertriglyceridemia (HT) in subjects with HIV [abstract]. Fourth international workshop on adverse drug reactions and lipodystrophy in HIV, San Diego, CA, September 2002. Abstract 49.
15. Smith SR, Lovejoy JC, Greenway F, et al. 2001. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism, 50:425-35.